India Globalization Capital (IGC) Reports Q2 Loss of $0.05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- Qualcomm (QCOM) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 Guidance
- Intel shares fall as competitor reports record results
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- SanDisk shares fall on election and chip sector pressure
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
IGC Reports Financial Results for the Quarter Ended June 30, 2022
August 8, 2022 6:00 AM EDTPOTOMAC, Md.--(BUSINESS WIRE)-- India Globalization Capital, Inc. (IGC or the Company) (NYSE American: IGC) announces its financial results for the three months ended June 30, 2022, which is the first quarter of the Companys 2023 fiscal year.
The highlights for the quarter are:
The Company has submitted a protocol to the U.S. Food and Drug Administration (FDA) titled A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled, trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimers disease. The protocol is powered at 146... More


